Cargando…

The Lived Experience of Patients Utilizing Second-Generation Direct-Acting Antiviral for Treatment of Chronic Hepatitis C Virus Infection: A Phenomenological Analysis

Hepatitis C is a global public health problem, and the aim of this study was to understand the experiences of patients with hepatitis C using second-generation antivirals. In-depth interviews were conducted with ten outpatients, cognitively capable of reporting their experience, followed up at a uni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nascimento, Yone de Almeida, Silva, Luciana Diniz, Ramalho de Oliveira, Djenane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566709/ https://www.ncbi.nlm.nih.gov/pubmed/36231842 http://dx.doi.org/10.3390/ijerph191912540

Ejemplares similares

The Subjective Experience of Using Medications: What We Know and the Paths Forward
por: de Almeida Nascimento, Yone, et al.
Publicado: (2021)

Decision-Making Process in Comprehensive Medication Management Services: From the Understanding to the Development of a Theoretical Model
por: Oliveira, Isabela Viana, et al.
Publicado: (2020)

Reduced work absenteeism in patients with hepatitis C treated with second‐generation direct‐acting antivirals
por: Lindgren, Peter, et al.
Publicado: (2020)

Drug interactions among older adults followed up in a comprehensive medication management service at Primary Care
por: dos Santos, Tayane Oliveira, et al.
Publicado: (2019)

Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12
por: Werner, Christoph R, et al.
Publicado: (2016)

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
por: Frisk, P., et al.
Publicado: (2018)

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
por: Teixeira, Rosângela, et al.
Publicado: (2013)

Understanding the meaning of medications for patients: The medication experience
por: Shoemaker, Sarah J., et al.
Publicado: (2007)

Factors associated with the identification of drug therapy problems among older patients in Primary Health Care
por: Dias, Bianca Menezes, et al.
Publicado: (2022)

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis
por: Suwanthawornkul, Thanthima, et al.
Publicado: (2015)

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Soriano, Vicente, et al.
Publicado: (2022)

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C
por: Lin, Sheng Feng, et al.
Publicado: (2020)

Clinical Results of Comprehensive Medication Management Services in Primary Care in Belo Horizonte
por: Neves, Carina de Morais, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

Medication Therapy Management: 10 Years of Experience in a Large Integrated Health Care System
por: Ramalho de Oliveira, Djenane, et al.
Publicado: (2010)

Medication Therapy Management: 10 Years of Experience in a Large Integrated Health Care System
por: de Oliveira, Djenane Ramalho, et al.
Publicado: (2020)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals
por: ISHIKAWA, TORU, et al.
Publicado: (2016)

Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents
por: Hong, Jenny, et al.
Publicado: (2020)

Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus
por: Cachay, Edward R, et al.
Publicado: (2019)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism
por: Sparvoli, Jucéli Márcia Hendges, et al.
Publicado: (2022)

Competencies for the provision of comprehensive medication management services in an experiential learning project
por: Mendonça, Simone de Araújo Medina, et al.
Publicado: (2017)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Development, Testing and Results of a Patient Medication Experience Documentation Tool for Use in Comprehensive Medication Management Services
por: Redmond, Stephanie, et al.
Publicado: (2019)

Healthcare Utilisation and Clinical Outcomes in Older Cardiovascular Patients Receiving Comprehensive Medication Management Services: A Nonrandomised Clinical Study
por: Brajković, Andrea, et al.
Publicado: (2022)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Ramadan, Mohammad Said, et al.
Publicado: (2022)

Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C
por: Jiang, Xinyi, et al.
Publicado: (2021)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
por: Holzmann, Iandra, et al.
Publicado: (2018)

The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals
por: Fayed, Hanan Mahmoud, et al.
Publicado: (2020)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h6bc3ird3m17jcgiqulqtta7q9